Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, wherein indole and an indole-based compound contained in a pharmaceutical composition used in the method of the present invention can reduce the polyglutamine aggregation through decreasing reactive oxygen species production and increasing the activity of chaperone and autophagy.
Type:
Grant
Filed:
May 20, 2014
Date of Patent:
July 19, 2016
Assignee:
NATIONAL TAIWAN NORMAL UNIVERSITY
Inventors:
Guey-Jen Lee-Chen, Hsiu-Mei Hsieh, Ching-Fa Yao
Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
Type:
Grant
Filed:
July 25, 2014
Date of Patent:
June 28, 2016
Assignee:
Oncoceutics, Inc
Inventors:
Martin Stogniew, Joshua E. Allen, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson
Abstract: Ataxia-telangiectasia (A-T) is a progressive degenerative disorder that results in major neurological disability. In A-T patients, necropsy has revealed atrophy of all cerebellar cortical layers with extensive Purkinje and granular cell loss. We have previously identified an increase in phospho-p38MAPK levels, which was accompanied by downregulation of Bmi-1 and upregulation of p21, as key components of the mechanism causing defective proliferation of neural stem cells (NSCs) isolated from subventricular zone (SVZ) of Atm-null mice. Our results demonstrate that restoration of NSCs by pharmacologic inhibition of p38MAPK signaling has the potential to treat neurological defects of A-T. This study provides new insights into the therapeutic strategy targeting NSCs rather than replacing impaired neurons not only for A-T, but for other neurodegenerative disorders as well.
Abstract: Disclosed are compositions and methods for treating and/or preventing infections in mammals, by administering to a mammal a therapeutically effective amount of at least one defensin-like molecule, e.g., in a composition that includes such molecule. Also disclosed are kits that include such molecules, or compositions that include such molecules, as well as instructions for using such molecules to treat a mammal.
Type:
Grant
Filed:
June 6, 2013
Date of Patent:
May 31, 2016
Assignee:
University of Maryland, Baltimore
Inventors:
Erik De Leeuw, Alexander D. Mackerell, Jr.
Abstract: The present invention provides a pharmaceutical composition for enhancement of adiponectin production, treatment or prevention of hypoadiponectinemia, and the like, comprising as an active ingredient an HMG-CoA reductase inhibitor.
Abstract: The present disclosure provides methods of treating (including ameliorating and/or preventing) pathogenic infections by administering a therapeutically effective amount of a prochelator. The present disclosure further provides pharmaceutical compositions and a kit comprising the prochelator therein.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
May 10, 2016
Assignee:
Duke University
Inventors:
Katherine J. Franz, Dennis J. Thiele, Marian Helsel, Richard Festa
Abstract: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases. The invention provides new compounds having improved solubility and/or potency, and methods for their use. In various aspects, the invention relates to the treatment of cancer. The invention provides methods for chemoprevention and prevention of tumor recurrence or metastasis. The invention further provides diagnostic techniques for treatment for certain cancer types. The invention utilizes specific inhibitors of CDK8/19 and/or measurement of CDK8 levels in a patient.
Type:
Grant
Filed:
February 1, 2013
Date of Patent:
April 26, 2016
Assignee:
SENEX BIOTECHNOLOGY INC
Inventors:
Igor B Roninson, Donald C Porter, Mark P Wentland
Abstract: An artificial tris-catecolate siderophore with a tripodal backbone and its conjugates with ampicillin and amoxicillin were synthesized. Both conjugates exhibited significantly enhanced in vitro antibacterial activities against Gram-negative species compared to the parent drugs, especially against P. aeruginosa. The conjugates appear to be assimilated by an induced bacterial iron transport process as their activities were inversely related to iron concentration. The easily synthesized tris-catecolate siderophores can be used with a variety of drugs as conjugates to target antibiotic-resistant Gram-negative bacteria.
Type:
Grant
Filed:
April 18, 2013
Date of Patent:
April 5, 2016
Assignee:
UNIVERSITY OF NOTRE DAME DU LAC
Inventors:
Marvin J. Miller, Cheng Ji, Patricia A. Miller
Abstract: Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for the treatment of facial wrinkling are provided.
Abstract: Described herein is a novel class of inhibitors of bacterial cell division. Several lines of evidence suggest the compounds disclosed herein specifically target the division process and have antibacterial activity in vitro and in vivo. The inhibitors are useful for treating subject in need of treatment for bacterial infections as will as for inhibiting bacterial growth, such as growth on contaminated surfaces.
Type:
Grant
Filed:
July 11, 2012
Date of Patent:
March 15, 2016
Assignee:
WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventors:
Douglas B. Weibel, Ye Jin Eun, Maoquan Zhou
Abstract: Methods of treating, preventing, or managing autoimmune inflammatory diseases and disorders including but not limited to spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, and rheumatoid arthritis by the administration of phosphodiesterase 4 (PDE4) inhibitors in combination with other therapeutics are disclosed. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Type:
Grant
Filed:
April 27, 2012
Date of Patent:
March 1, 2016
Assignee:
Celgene Corporation
Inventors:
Peter H. Schafer, Anita Gandhi, Lori Capone
Abstract: This disclosure relates, at least in part, to a method of treatment. In one embodiment, the method of treatment comprises administering to a subject in need of such treatment a first therapeutic agent including compound (1): or a pharmaceutically acceptable salt thereof in combination with a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
February 23, 2016
Assignee:
Oncoceutics, Inc.
Inventors:
Martin Stogniew, Joshua E. Allen, Richard S. Pottorf, Bhaskara Rao Nallaganchu, Gary Olson
Abstract: Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing a catecholamine backbone and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods, compositions, and compounds for the treatment of disorders including neurological disorders, neuropsychiatric disorders, and metabolic disorders are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes administering to the subject a therapeutically effective amount of the described compounds. A further method of promoting neuroprotection in a subject also is provided, which includes administering to the subject a therapeutically effective amount of the described compounds.
Abstract: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.
Type:
Grant
Filed:
January 10, 2011
Date of Patent:
February 9, 2016
Assignee:
COLD SPRING HARBOR LABORATORY
Inventors:
Timothy P. Tully, Filippo Cavalieri, Rusiko Bourtchouladze
Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.
Type:
Grant
Filed:
January 26, 2015
Date of Patent:
February 9, 2016
Assignee:
Wyeth LLC
Inventors:
Mahdi B. Fawzi, Tianmin Zhu, Syed M. Shah
Abstract: The present invention relates to a dietary supplement composition made of: linolenic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, 1%-20% alpha-tocopherol, and 7.5%-15% acai berry powder and a method to use this composition to supplement the diet of a domestic animal, such as a canine or an equine.
Abstract: Pyridone and pyrazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Type:
Grant
Filed:
August 31, 2011
Date of Patent:
February 2, 2016
Assignees:
Genentech, Inc., Gilead Connecticut, Inc.
Inventors:
Kevin S. Currie, Xiaojing Wang, Wendy B. Young
Abstract: Provided are an agent for the treatment and/or prophylaxis of a mood disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (I) wherein R1 represents aryl or the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof, and the like.
Abstract: The present invention relates to a dietary supplement composition made of: linolenic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, and 1%-20% alpha-tocopherol and a method to use this composition to supplement the diet of a domestic animal, such as a canine or an equine.